If I had to guess the sort of healthcare company that would get a premium acquisition offer, Lincare (Nasdaq:LNCR) would be low on my list, as relatively few buyers would want to pay a premium to get into a business that is beset by constant reimbursement pressures. But, as the old saying goes, you only need one buyer to make a deal and Lincare found that one.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

In a deal that reverses a spin-out from nearly 25 years ago, German industrial gases company Linde will be acquiring Lincare for $4.6 billion in total considerations. That works out to $41.50 per share for Lincare's shareholders; a 22% premium to Friday's closing price (which had been moving up on takeover rumors) and a whopping 67% premium to the stock's three-month average price.

SEE: Analyzing An Acquisition Announcement

What Is Linde Buying?
Linde is getting the nation's leading provider of in-home oxygen/respiratory therapy, with a national share of about 28%. Lincare has long been an exceptionally well-run company with strong management; management has built Lincare through a series of tuck-in acquisitions and has navigated the company through several challenging periods.

A lot of those challenges come from the nature of the business. Like home-care providers including Amedisys (Nasdaq:AMED) and LHC Group (Nasdaq:LHCG), Lincare gets a large amount of its revenue from the federal government - roughly 60% of the company's revenue comes from Medicare or Medicaid. With a large part of revenue subject to competitive bidding, a three-year limit on equipment rentals and ongoing rate cuts, the operating environment has been simply brutal of late.

SEE: Investing In The Healthcare Sector

And yet, Lincare has persevered. Lincare has managed to leverage its scale to drive down operating costs, and has repurchased roughly one-third of its shares over the past five years. At the same time, the company has tried to diversify away from its heavy dependence on oxygen therapy by building a specialty pharmaceutical business centered on anti-coagulation and pulmonary therapy.

Why Pay so Much?
To a certain extent, I can appreciate why Linde wants to expand its healthcare operations. The industrial gas business is very competitive and highly cyclical, and healthcare is a popular choice for companies looking to diversify (consider the example of Fujifilm). Moreover, other industrial gas companies like Air Products (NYSE:APD) and Praxair (NYSE:PX) have moved into the healthcare field to varying degrees (in fact, Linde bought Air Products' southern European healthcare business earlier this year).

SEE: Healthcare Funds: Give Your Portfolio A Booster Shot

All of that said, Linde is certainly paying a lot for this diversification. Lincare's market share is solid, and lends certain operating advantages, but it offers no respite to reimbursement pressures. Moreover, I find it hard to believe that there were competitive bidders forcing Linde to pay so much. As it stands, Linde is paying almost $10 (or 30%) more than I thought Lincare was worth, and the deal probably won't be materially additive until 2015 - and that's assuming there's no major downturn in reimbursement in the meanwhile.

The Bottom Line
Kudos to Lincare management for securing a great deal for its shareholders. To sell a Medicare-dependent business at a 25% premium to its all-time-high deserves more than just a pat on the back. Honestly, I cannot see why any Lincare shareholder wouldn't be thrilled with this deal.

I would not extrapolate this deal across the wider healthcare services group. True, there are quality names out there like AmSurg (Nasdaq:AMSG), Acadia Healthcare (Nasdaq:ACHC) and HCA (NYSE:HCA), and this bid from Linde proves that there's always a chance for a premium bid, but I just don't see a surplus of buyers willing to pay such high premiums today.

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Investing

    How to Ballast a Portfolio with Bonds

    If January and early February performance is any guide, there’s a new normal in financial markets today: Heightened volatility.
  2. Stock Analysis

    Performance Review: Emerging Markets Equities in 2015

    Find out why emerging markets struggled in 2015 and why a half-decade long trend of poor returns is proving optimistic growth investors wrong.
  3. Investing

    Don't Freak Out Over Black Swans; Be Prepared

    Could 2016 be a big year for black swans? Who knows? Here's what black swans are, how they can devastate the unprepared, and how the prepared can emerge unscathed.
  4. Investing News

    Today's Sell-off: Are We in a Margin Liquidation?

    If we're in market liquidation, is it good news or bad news? That party depends on your timeframe.
  5. Investing News

    Bank Stocks: Time to Buy or Avoid? (WFC, JPM, C)

    Bank stocks have been pounded. Is this the right time to buy or should they be avoided?
  6. Stock Analysis

    Why the Bullish Are Turning Bearish

    Banks are reducing their targets for the S&P 500 for 2016. Here's why.
  7. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  8. Stock Analysis

    Analyzing Sirius XM's Return on Equity (ROE) (SIRI)

    Learn more about the Sirius XM's overall 2015 performance, return on equity performance and future predictions for the company's ROE in 2016 and beyond.
  9. Stock Analysis

    Will Virtusa Corporation's Stock Keep Chugging in 2016? (VRTU)

    Read a thorough review and analysis of Virtusa Corporation's stock looking to project how well the stock is likely to perform for investors in 2016.
  10. Stock Analysis

    Analyzing Porter's Five Forces on JPMorgan Chase (JPM)

    Examine the major money-center bank holding firm, JPMorgan Chase & Company, from the perspective of Porter's five forces model for industry analysis.
RELATED FAQS
  1. When does a growth stock turn into a value opportunity?

    A growth stock turns into a value opportunity when it trades at a reasonable multiple of the company's earnings per share ... Read Full Answer >>
  2. What is the formula for calculating EBITDA?

    When analyzing financial fitness, corporate accountants and investors alike closely examine a company's financial statements ... Read Full Answer >>
  3. How do I calculate the P/E ratio of a company?

    The price-earnings ratio (P/E ratio) is a valuation measure that compares the level of stock prices to the level of corporate ... Read Full Answer >>
  4. How do you calculate return on equity (ROE)?

    Return on equity (ROE) is a ratio that provides investors insight into how efficiently a company (or more specifically, its ... Read Full Answer >>
  5. How do you calculate working capital?

    Working capital represents the difference between a firm’s current assets and current liabilities. The challenge can be determining ... Read Full Answer >>
  6. What is the formula for calculating the current ratio?

    The current ratio is a financial ratio that investors and analysts use to examine the liquidity of a company and its ability ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center